ProCE Banner Activity

KRYSTAL-12: Phase III Trial of Adagrasib vs Docetaxel in Previously Treated Advanced KRASG12C- Mutated NSCLC

Conference Coverage

Primary analysis of the KRYSTAL-12 trial demonstrated that adagrasib significantly improved PFS vs docetaxel in patients with previously treated KRASG12C-mutated non-small-cell lung cancer.

Released: June 04, 2024

Expiration: June 03, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.